Insights Into Participating in Studies for Uterine Cancer
Study Details
Study Description
Brief Summary
Clinical study participation has historically been heavily biased toward specific demographics.
Several people will be invited to enroll in this trial so that it may collect a variety of data about uterine cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.
People with uterine cancer who are invited to take part in medical study will benefit from the analysis of the data.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of patients who decide to enroll in a uterine cancer clinical research [3 months]
- Rate of patients who remain in a uterine cancer clinical trial to trial completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
-
Diagnosis of uterine cancer
-
No prior treatment for uterine cancer
Exclusion Criteria:
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
-
Enrolled in another research study
-
Inability to provide written informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Power Life Sciences | San Francisco | California | United States | 94107 |
Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Filippova OT, Leitao MM. The current clinical approach to newly diagnosed uterine cancer. Expert Rev Anticancer Ther. 2020 Jul;20(7):581-590. doi: 10.1080/14737140.2020.1782750. Epub 2020 Jun 22.
- Torres D, Myers JA, Eshraghi LW, Riley EC, Soliman PT, Milam MR. Risk factors for the development of uterine cancer in breast cancer survivors: an army of women study. Ann Surg Oncol. 2015;22(6):1974-9. doi: 10.1245/s10434-014-4193-5. Epub 2014 Nov 1.
- Wang Z, Guo E, Yang B, Xiao R, Lu F, You L, Chen G. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer. Gynecol Oncol. 2021 Nov;163(2):358-363. doi: 10.1016/j.ygyno.2021.08.029. Epub 2021 Sep 8.
- 82665307